Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20442680 | 0.89 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL20325313 | 0.85 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL22560560 | 0.83 | EPHX2 (0.33) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL20324957 | 0.82 | EPHX2 (0.35) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL20325432 | 0.81 | EPHX2 (0.37) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL22297391 | 0.80 | CYP4F2 (0.38) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL18611784 | 0.80 | CYP4F2 (0.38) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL18551622 | 0.80 | CYP4F2 (0.38) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL22047832 | 0.80 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 | |
| SCHEMBL18612313 | 0.80 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3EPHX2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | SLC6A2 4551/4885SLC6A4 4453/4885SLC6A3 4243/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | SLC6A2 4551/4885SLC6A4 4453/4885SLC6A3 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.